Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04782687 · ClinicalTrials.gov registry record · Phase 2
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
A Phase 2 study of Multiple Myeloma and Plasma Cell Myeloma, sponsored by US Oncology Research.
- Active
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
- 10
- Study locations
NCT04782687: Active Phase 2 study of Multiple Myeloma and Plasma Cell Myeloma, sponsored by US Oncology Research.
NCT04782687 is a Phase 2 study of Multiple Myeloma and Plasma Cell Myeloma that is active but no longer recruiting, run by US Oncology Research. The registered enrollment target is 73 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (87% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04782687, a Phase 2 study of Multiple Myeloma and Plasma Cell Myeloma, is active but no longer recruiting, sponsored by US Oncology Research.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a single-arm, phase II, open-label trial to investigate the effects of selinexor (S) in combination with daratumumab, lenalidomide, and dexamethasone (DRd) for first-line treatment of multiple myeloma (MM). FDA has approved selinexor plus dexamethasone in multiple myeloma after four prior therapies, and DRd is also already approved by the FDA for multiple myeloma. This study will use all four (S-DRd) together to treat MM as an initial treatment.
Primary Outcome
percentage of patients who had complete response. Complete response is when patients achieve a negative immunofixation on the serum and urine and who also have an appearance of a soft tissue plasmacytomas and achieve less than or equal to 5 percent (%) plasma cells in the bone marrow.
Conditions Studied
Interventions
- DRUG Selinexor
- DRUG Lenalidomide
- DRUG Daratumumab
- DRUG Dexamethasone Oral
Study Locations (10)
Texas
- Texas Oncology, P.A. - Austin
- Texas Oncology, P.A. - Fort Worth
- Texas Oncology, P.A. - San Antonio
- Texas Oncology, P.A. - Tyler
Arizona
- Arizona Oncology Associates, PC - HOPE - Tucson
Colorado
- Rocky Mountain Cancer Centers - Denver
Maryland
- Maryland Oncology Hematology, P.A. - Columbia
New York
- New York Oncology Hematology, P.C. - Albany
Oregon
- Willamette Valley Cancer Institute and Research Center - Eugene
Virginia
- Virginia Cancer Specialists, PC - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2021-09-10 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 2 |
What the registry record for NCT04782687 still lists
NCT04782687 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (87% lower).
The record links to 6 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Selinexor is the first listed.
NCT04782687 lists 10 locations in 7 states (Texas, Arizona, Colorado).
Frequently Asked Questions
What is clinical trial NCT04782687 about?
NCT04782687 is a clinical study titled "Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma". This is a single-arm, phase II, open-label trial to investigate the effects of selinexor (S) in combination with daratumumab, lenalidomide, and dexamethasone (DRd) for first-line treatment of multiple myeloma (MM). FDA has approved selinexor plus dexamethasone in multiple myeloma after four prior t...
What is the current status of trial NCT04782687?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2021-09-10. Estimated completion is 2026-05-31.
What conditions does trial NCT04782687 study?
This clinical trial studies the following conditions: Multiple Myeloma, Plasma Cell Myeloma, Myeloma Multiple, Myeloma, Plasma Cell, Kahler Disease.
What interventions are being tested in trial NCT04782687?
The interventions under investigation include: Selinexor (DRUG), Lenalidomide (DRUG), Daratumumab (DRUG), Dexamethasone Oral (DRUG).
Who is sponsoring clinical trial NCT04782687?
This trial is sponsored by US Oncology Research, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04782687 being conducted?
This trial has 10 study locations across Arizona, Colorado, Maryland, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04782687's enrollment target sits among peer trials
73 209th of 438 higher than 230 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI